Steroids Increase Infection Risk With CAR T-Cell Therapy in NHL Steroids Increase Infection Risk With CAR T-Cell Therapy in NHL
Steroids and multiple prior treatments markedly increase the risk of infection following CAR T-cell therapy in patients with high-grade B-cell non-Hodgkin's lymphoma, UK clinicians have found.Medscape News UK (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

ASH: CAR T-Cell Therapy Promising for Relapsed/Refractory iNHL
WEDNESDAY, Dec. 9, 2020 -- Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, is promising for the treatment of relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 9, 2020 Category: Pharmaceuticals Source Type: news

New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma
Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained ...
Source: Roche Media News - December 7, 2020 Category: Pharmaceuticals Source Type: news

New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma
Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained ...
Source: Roche Investor Update - December 7, 2020 Category: Pharmaceuticals Source Type: news

CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma
(Dana-Farber Cancer Institute) A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 5, 2020 Category: International Medicine & Public Health Source Type: news

Hodgkin's vs. Non-Hodgkin's Lymphoma
Title: Hodgkin's vs. Non-Hodgkin's LymphomaCategory: Diseases and ConditionsCreated: 1/31/2007 12:00:00 AMLast Editorial Review: 11/10/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 10, 2020 Category: Cancer & Oncology Source Type: news

Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting
Basel, 5 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukaemia, multiple myeloma (MM) and haemophilia A, these data highlight the strength and breadth o f Roche’s haematology portfolio and pipeline, and commitment to de...
Source: Roche Media News - November 5, 2020 Category: Pharmaceuticals Source Type: news

Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting
Basel, 5 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukaemia, multiple myeloma (MM) and haemophilia A, these data highlight the strength and breadth o f Roche’s haematology portfolio and pipeline, and commitment to de...
Source: Roche Investor Update - November 5, 2020 Category: Pharmaceuticals Source Type: news

14.10.20: Not intended for U.S. and UK Media
Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's LymphomaPhase III study CHRONOS-3 in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL) who have received one or more lines of prior treatment meets primary endpoint / Safety and tolerability observed in the trial were generally consistent with previously published data on the individual components of the combination and no new safety signals were identified / Copanlisib is already approved in the U.S. under accelerated approval based on overall response rate (ORR) of 104 adu...
Source: Bayer IR Newsfeed: Events - October 14, 2020 Category: Pharmaceuticals Source Type: news

Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug
(Society of Nuclear Medicine and Molecular Imaging) A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine. When used in combination with rituximab, 177Lu-lilotomab-satetraxetan was shown to substantially increase rituximab binding and rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) activity, resulting in significant tumor growth delay in a non-Hodgkin's lymphoma mouse model. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 8, 2020 Category: Cancer & Oncology Source Type: news

Many Non-Hodgkin's Lymphoma patients can skip radiation, collaborative study finds
(University of Arizona Health Sciences) Skipping radiation and receiving less chemotherapy may become the new standard of care for some lymphoma patients, according to a recent collaborative University of Arizona Health Sciences-led study. Published in the Journal of Clinical Oncology, the study suggests using a positron emission tomography (PET) scan after three cycles of a combination of chemotherapy drugs known as R-CHOP. If the patient's scan is negative, they can proceed with another round of R-CHOP to complete their treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 6, 2020 Category: Cancer & Oncology Source Type: news

FDA grants Fast Track designation to Calibr's 'switchable' CAR-T cell cancer therapy
(Scripps Research Institute) The US Food and Drug Administration has granted Fast Track designation to a novel 'switchable' CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process. The therapy is currently being evaluated as a treatment for B-cell malignancies, a class of blood cancers that includes non-Hodgkin's lymphoma and chronic lymphocytic leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 1, 2020 Category: International Medicine & Public Health Source Type: news

Non-Hodgkin's Lymphoma
Title: Non-Hodgkin's LymphomaCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 8/31/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 31, 2020 Category: Cancer & Oncology Source Type: news

Mayo Clinic Q and A: New blood cancer treatment options with chimeric antigen receptor-T cell therapy
Dear Mayo Clinic: My brother was diagnosed with non-Hodgkin lymphoma a few years ago and has had several recurrences. I was reading about something called chimeric antigen receptor-T cell therapy (CAR-T cell therapy) and was wondering how it works and if he might be a candidate for it? Answer: CAR-T cell therapy is a relatively new treatment that [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 29, 2020 Category: Databases & Libraries Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s CD20xCD3 bispecific cancer immunotherapy mosunetuzumab recognising its potential in follicular lymphoma
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its investigational CD20xCD3 T-cell engaging bispecific mosunetuzumab has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior systemic therapies.“We are pleased that the FDA has granted Breakthrough Therapy Designation to mosunetuzumab, recognising the promising early efficacy data for this molecule and the remaining unmet need in follicular lymphoma,” said Levi Gar...
Source: Roche Investor Update - July 14, 2020 Category: Pharmaceuticals Source Type: news

Judge Puts Cloud Over Settlement of Roundup Cancer Claims
An agreement for the weedkiller ’s maker to pay more than $10 billion to end litigation may not get court approval. (Source: NYT Health)
Source: NYT Health - July 7, 2020 Category: Consumer Health News Authors: Patricia Cohen Tags: Hazardous and Toxic Substances Suits and Litigation (Civil) Defoliants and Herbicides Non-Hodgkin ' s Lymphoma Bayer AG Monsanto Company Chhabria, Vince Girdhari Feinberg, Kenneth R Roundup Source Type: news

Highlights in Non-Hodgkin Lymphoma From ASCO 2020 Highlights in Non-Hodgkin Lymphoma From ASCO 2020
Highlights in non-Hodgkin lymphoma from the ASCO 2020 virtual annual meeting include new data on CAR T cells in relapsed/refractory NHL, and Bcl-2 inhibition and chemoimmunotherapy in Richter syndrome.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Blood cancer symptoms: Swelling in this part of the body could be a warning sign
BLOOD CANCER - there are three main types: leukaemia, lymphoma and myeloma. Those with non-Hodgkin lymphoma may experience swelling, but where in the body? (Source: Daily Express - Health)
Source: Daily Express - Health - June 18, 2020 Category: Consumer Health News Source Type: news

Roche presents updated data on novel CD20xCD3 bispecific cancer immunotherapy glofitamab in people with heavily pre-treated non-Hodgkin lymphomas
Basel, 12 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced updated data on one of its investigational CD20xCD3 T-cell engaging bispecific antibodies, glofitamab (formerly known as CD20-TCB), in people with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). Updated results from the phase I dose-escalation NP30179 study [NCT03075696] of glofitamab, administered via intravenous infusion for a fixed-duration of up to 12 21-day cycles, showed durable complete responses (CRs) in heavily pre-treated patients who had received a median of three prior lines of therapy. These data feature in an oral presentation (...
Source: Roche Investor Update - June 12, 2020 Category: Pharmaceuticals Source Type: news

Caron A. Jacobson, MD, on the Interim Phase II ZUMA-5 Study Safety and Efficacy Findings
The study evaluated the use of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2020 Category: Cancer & Oncology Authors: Caron A. Jacobson, MD Source Type: news

Rituximab + Chemo Ups Survival in Pediatric B-Cell Non-Hodgkin Lymphoma
THURSDAY, June 4, 2020 -- For children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin lymphoma, rituximab added to standard lymphomes malins B (LMB) chemotherapy prolongs event-free survival, according to a study published in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2020 Category: Pharmaceuticals Source Type: news

Phase III results show rituximab excels against pediatric Burkitt lymphoma
(University of Colorado Anschutz Medical Campus) Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2020 Category: International Medicine & Public Health Source Type: news

A new immunotherapeutic agent for children and adolescents with advanced lymphoma
(Comprehensive Cancer Centre Gustave Roussy) The excellent results of the phase III international paediatric study, Inter-B-NHL ritux 2010, have been published in the New England Journal of Medicine. It establishes a new standard treatment with an improved cure rate for children with advanced non-Hodgkin lymphoma, mainly Burkitt lymphoma. It supports the value of an immunotherapeutic agent, which was authorised in March 2020 by the European Commission for the treatment of a rare childhood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2020 Category: Cancer & Oncology Source Type: news

Interim Phase II ZUMA-5 Results Show Promise for Axi-Cel in R/R iNHL
Results showed that axicabtagene ciloleucel demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

A new therapeutic target turns the immune system against lymphoma
(Ecole Polytechnique F é d é rale de Lausanne) EPFL scientists have identified a key mechanism that tumor cells use to take advantage of and avoid detection from the immune system. Targeting this mechanism offers a new therapeutic strategy for cancers like Non-Hodgkin lymphoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 23, 2020 Category: Cancer & Oncology Source Type: news

NFCR-backed technology receives FDA's assent for lymphoma clinical trials
(National Foundation for Cancer Research) National Foundation for Cancer Research-backed drug and drug delivery technology receives assent from US Food and Drug Administration for T-cell non-Hodgkin's lymphoma clinical trials. The milestone represents another example of promising translational cancer research supported by the organization and its donors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 12, 2020 Category: Cancer & Oncology Source Type: news

Caution: Higher Radiation Dose Linked to Worse NHL Outcomes Caution: Higher Radiation Dose Linked to Worse NHL Outcomes
Among patients with non-Hodgkin lymphoma who underwent reduced-intensity conditioning for stem cell transplant, overall survival was lower if they received a higher dose of radiation.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 21, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

A randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared...
The objective of this study was to compare the safety and antitumor activity of F14512 and etoposide phosphate in dogs with spontaneous non-Hodgkin lymphoma and to investigate the potential benefit of F14512 in P-glycoprotein overexpressing lymphomas. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 19, 2020 Category: International Medicine & Public Health Source Type: news

Young Cancer Survivors at Higher Risk for Hospitalization
Risks most elevated for survivors of leukemia, CNS tumors, CRC, non - Hodgkin lymphoma, breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 12, 2020 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Oncology, Pediatrics, Journal, Source Type: news

Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, Lymphoma
Patients with either relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease. (Source: CancerNetwork)
Source: CancerNetwork - February 8, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma
(University of Texas M. D. Anderson Cancer Center) According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 5, 2020 Category: Cancer & Oncology Source Type: news

FDA clears investigational new drug application for Calibr's 'switchable' CAR-T therapy
(Scripps Research Institute) Calibr, the drug discovery and development division of Scripps Research, today announced that the US Food and Drug Administration has given clearance to the Investigational New Drug (IND) application for Calibr's 'switchable' CAR-T cell therapy, which is being evaluated for the treatment of certain cancers, including relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 3, 2020 Category: International Medicine & Public Health Source Type: news

Nitrite Consumption May Up Risk for Non-Hodgkin Lymphoma
THURSDAY, Jan. 30, 2020 -- Nitrite consumption is associated with an increased risk for non-Hodgkin lymphoma (NHL), according to a meta-analysis published online Jan. 17 in Scientific Reports. Mengxia Yu, from Zhejiang University in Hangzhou, China,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 30, 2020 Category: Pharmaceuticals Source Type: news

Georgia Sterilization Plant Hit with Hefty Fines for EtO Violation
An Atlanta, GA-based medical sterilization plant is learning an expensive lesson after missing a critical deadline related to ethylene oxide (EtO) pollution controls. Sterilization Services of Georgia received a permit on Nov. 7 to use EtO to sterilize medical devices, but the company was supposed to install filters to reduce the gas by Dec. 31. The filters were fully operational as of Jan. 18, according to a Jan. 20 letter, but the Georgia Environmental Protection Department (EPD) fined the company $3,000 for each day beyond the deadline that the filters were not connected. In the letter to the Geo...
Source: MDDI - January 29, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: Sterilization Source Type: news

Hashimoto Thyroiditis in Primary Thyroid Non-Hodgkin Lymphoma Hashimoto Thyroiditis in Primary Thyroid Non-Hodgkin Lymphoma
How prevalent is Hashimoto thyroiditis in cases of primary thyroid lymphoma, and what is its etiology? Is Hashimoto thryoiditis a necessary condition for the development of PTL?American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 21, 2020 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Report: Roundup cases climb as Bayer edges closer to settlement
The mediator appointed to resolve lawsuits filed against Monsanto Co. involving its Roundup weedkiller said Bayer AG may be weeks away from settling claims that have ballooned to more than 75,000. The plaintiffs in the cases contend that their use of Roundup caused them to develop non-Hodgkin's lymphoma. In an interview with Bloomberg Thursday, Ken Feinberg reiterated his sentiment that he's “cautiously optimistic” about reaching a deal within a month. But he said the caseload — whic h Bayer,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 17, 2020 Category: Biotechnology Authors: Erik Siemers Source Type: news

Using HDAC3 Inhibitors to Reverse CREBBP Mutations in Lymphomas
This research could potentially pave the way for possible immunotherapy approaches for common forms of non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - January 13, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

The Big Number: Why your risks for 7 types of cancer could be reduced with physical activity
Research shows several exercises can be effective against these cancers: breast, colon, endometrial, kidney, liver, multiple myeloma and non-Hodgkin lymphoma. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - January 12, 2020 Category: Consumer Health News Authors: Linda Searing Source Type: news

Exercise may reduce risk for cancer by as much as 25 percent
People who engaged in physical activity as recommended by the NIH were able to reduce their risk for colon and breast cancers, as well as endometrial cancer, kidney cancer, myeloma, liver cancer and non-Hodgkin lymphoma. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 26, 2019 Category: Consumer Health News Source Type: news

Medical News Today: What to know about non-Hodgkin lymphoma
This article looks at their types, symptoms, diagnosis, and treatment. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 11, 2019 Category: Consumer Health News Tags: Lymphoma Source Type: news

Monsanto's former CEO ordered to testify in St. Louis Roundup trial
Former Monsanto Co. Chairman and CEO Hugh Grant has been ordered to testify in persons at a Roundup trial in St. Louis in January. Grant, who led St. Louis-based Monsanto from 2003 until the company was sold to Bayer AG of Germany for $63 billion in 2018, was subpoenaed by lawyers for plaintiff Sharlean Gordon, who contends the Roundup weedkiller caused her non-Hodgkin lymphoma. The trial is scheduled to begin Jan. 27 in St. Louis County Circuit Court. Grant's lawyers have been fighting the subpoena,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 10, 2019 Category: Biotechnology Authors: Greg Edwards Source Type: news

Lenalidomide/Rituximab Combo Improves PFS in Subgroup of Patients with NHL
Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Gina Columbus Source Type: news

No radiation needed for many aggressive non-Hodgkin's lymphoma patients
(SWOG) Most people diagnosed with the most common type of non-Hodgkin's lymphoma can safely skip radiation treatment after a clear PET scan, according to new clinical trial results released today at the 61st American Society of Hematology (ASH) Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 8, 2019 Category: Cancer & Oncology Source Type: news

An Off-the-Shelf Drug to Rival CAR T Cells:'Very Exciting'An Off-the-Shelf Drug to Rival CAR T Cells:'Very Exciting '
A novel bispecific antibody, mosunetuzumab, has shown complete remissions in patients with poor prognosis non-Hodgkin's lymphoma, even those previously treated with CAR T cells.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 7, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche announces new data on novel CD20-CD3 bispecific cancer immunotherapies in people with difficult-to-treat lymphomas
Roche today announced new data on two investigational CD20-CD3 T-cell engaging bispecific antibodies, mosunetuzumab and CD20-TCB, in people with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2019 Category: Pharmaceuticals Source Type: news

Lymphoma patients may have new path to remission, even when CAR T therapy fails
(University of Pennsylvania School of Medicine) A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2019 Category: Cancer & Oncology Source Type: news

Married couple and son, 17, ALL battling cancer and have put their family restaurant up for sale
Kathy Desclefs, of Jacksonville, Florida, has been battling non-Hodgkin's lymphoma for five years. This year, her husband Benoit and her son Luke were also diagnosed with cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - December 5, 2019 Category: Consumer Health News Source Type: news

FDA Takes Action to Reduce EtO Use
Shutdowns earlier this year of two facilities that use ethylene oxide (EtO) to sterilize medical devices prompted FDA to monitor for supply shortages in the industry because EtO is such a popular sterilization method for medical devices. This week the agency revealed steps it will take to reduce medtech's reliance on EtO sterilization. EtO is a flammable, colorless gas used to sterilize equipment and plastic devices that cannot be sterilized by steam, such as medical equipment. In fact, about half of all sterilized medical devices undergo sterilization using this gas. Breathi...
Source: MDDI - November 25, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Sterilization Regulatory and Compliance Source Type: news

Radiation From CT Scans Linked to Thyroid Cancer, Leukemia
Elevated risk stronger in women than men; risk for non - Hodgkin lymphoma increased in patients ≤ 45 (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 21, 2019 Category: Cancer & Oncology Tags: Endocrinology, Family Medicine, Internal Medicine, Emergency Medicine, Oncology, Radiology, Journal, Source Type: news

B.C. man sues Monsanto, Bayer, alleging Roundup herbicide caused his cancer
Cliff Sissons of Cranbrook, B.C., is suing the makers of the well-used herbicide, alleging exposure over the years caused him to develop non-Hodgkin's lymphoma. The maker of Roundup says the product is safe. (Source: CBC | Health)
Source: CBC | Health - October 18, 2019 Category: Consumer Health News Tags: News/Canada/British Columbia Source Type: news